All relevant data are within the paper.

Introduction {#sec005}
============

Cutaneous leishmaniasis (CL) is a disease caused by various *Leishmania* species affecting an estimated 0.7--1.2 million people each year in the Americas, the Mediterranean basin, the Middle East and Central Asia. In 2013, 95% of the cases reported to WHO occurred in 15 countries: Afghanistan, Algeria, Brazil, Colombia, Honduras, Iran (Islamic Republic of), Morocco, Nicaragua, Pakistan, Peru, Saudi Arabia, Syrian Arab Republic, Tunisia, Turkey, and Yemen \[[@pntd.0006141.ref001],[@pntd.0006141.ref002]\]. In 2014, over 153 000 cases were reported to WHO from 10 high-burden countries \[[@pntd.0006141.ref003],[@pntd.0006141.ref004]\].

Progress with the treatment of CL has been hampered by lack of investments in drug discovery and development, but also by the inconsistent methodologies that have been used to assess treatment effects \[[@pntd.0006141.ref005]\]. This has resulted in significant scientific and financial waste, as a sizable number of trials conducted over the years have generated only weak evidence for treatment recommendations.

These weaknesses were exposed by two Cochrane systematic reviews on Old-World \[[@pntd.0006141.ref006]\] and New-World \[[@pntd.0006141.ref007]\] CL (OWCL and NWCL; the latter recently updated \[[@pntd.0006141.ref008]\]). To correct these shortcomings, a series of steps were set in place towards achieving consensus on the main parameters that would help establish standardized, generally adoptable criteria in clinical investigations. This process started with a consultation jointly organized by the Special Programme for Research and Training in Tropical Diseases (WHO/TDR) and the World Health Organization Programme for Leishmaniasis at the Neglected Tropical Diseases Department (WHO/NTD) held in 2009, which led to a guidance paper in 2013 \[[@pntd.0006141.ref009]\] that aimed to (i) provide clinical investigators with guidance for the design, conduct, analysis and report of clinical trials of treatments for CL, whilst recognizing the complexity of the disease; and (ii) enhance the capacity for high-quality trials that fulfil the requirements of International Conference on Harmonization (ICH) and Good Clinical Practice (GCP) standards.

A network of clinical trial sites for NWCL (RedeLeish \[[@pntd.0006141.ref010]\]) was started with support by the Drugs for Neglected Diseases initiative (DNDi) in 2014, and discussions are underway to extend this network to OWCL (jointly with TDR).

Methods {#sec006}
=======

Basic parameters from the above-mentioned guidance paper were submitted to a group of OWCL and NWCL clinical trialists and discussed at workshops that took place in Tunisia (February 2016, hosted by the TDR regional training centre at Institute Pasteur, Tunis and organized by TDR) and in Brazil (June 2016, organized by DNDi). The meetings were attended by expert CL trialists representing 10 clinical study sites from 7 OWCL countries (Afghanistan, Burkina Faso, Ethiopia, Iran (Islamic Republic of), Morocco, Tunisia and Turkey) and 11 clinical study sites from 7 NWCL countries (Bolivia, Brazil, Colombia, Guatemala, Panama, Peru and Venezuela).

Results {#sec007}
=======

Consensus on key methodological issues in clinical trials of CL treatments {#sec008}
--------------------------------------------------------------------------

The degree of consensus and main issues are summarized in [Table 1](#pntd.0006141.t001){ref-type="table"} for OWCL and NWCL, along with the revised parameters after the two above mentioned consultations. A diagrammatic representation can be found in [Fig 1](#pntd.0006141.g001){ref-type="fig"}.

![Days counted from day treatment started.](pntd.0006141.g001){#pntd.0006141.g001}

10.1371/journal.pntd.0006141.t001

###### Agreement on key parameters by OWCL and NWCL clinical researchers.

'Standardized' criteria are those as proposed in the reference paper Olliaro et al, 2013^9^; 'updated' criteria are those resulting from the consultation.

![](pntd.0006141.t001){#pntd.0006141.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Key Parameters                                                                                                Standardised\              OWCL\                   NWCL\                   Updated          
                                                                                                                (Olliaro et al, 2013)^9^   10 sites, 7 countries   11 sites, 7 countries                    
  ------------------------------------------------------------------------------------------------------------- -------------------------- ----------------------- ----------------------- --------- ------ ---------------
  **Eligibility criteria**                                                                                                                                                                                  

  Only parasitologically-confirmed cases can be enrolled                                                        Yes                        100%                                            100%             Yes

  *Leishmania* species identification required for enrolment                                                    Yes/No                     100%                                                      100%   No

  *Leishmania* species identification required for analysis                                                     Yes/No                     100%                                            100%             Yes

  Baseline safety tests required (haematology, liver and renal function)[\*](#t001fn001){ref-type="table-fn"}   Yes/No                     100%                                            100%             Yes

  **Efficacy parameters**                                                                                                                                                                                   

  Re-epithelization of ulcerated lesions                                                                        Yes                        100%                                            100%             Yes

  Flattening of non-ulcerated lesions                                                                           Yes                        100%                                            100%             Yes

  Induration                                                                                                    No                         80%                                             91%              (Yes)

  Redness                                                                                                       No                         100%                                            100%             No

  **Time at which initial cure should be assessed**                                                                                                                                                         

  End of treatment                                                                                              No                                                 100%                              100%   No

  Day 42                                                                                                        Yes                        100%                                                      100%   Yes OW; No NW

  Day 90                                                                                                        Yes                        100%                                            100%             Yes

  **Time at which final cure should be assessed**                                                                                                                                                           

  Day 180 (6 months)                                                                                            Yes                        100%                                            100%             Yes

  Day 360 (12 months)                                                                                           Yes/No                                             100%                              100%   No

  **Follow-up counting from when?**                                                                                                                                                                         

  From the end of treatment                                                                                     No                                                 100%                              100%   No

  From the beginning of treatment                                                                               Yes                        100%                                            82%              (Yes)

  **Definition of treatment failure**                                                                                                                                                                       

  Day 42: \<50% re-epithelization (ulcer) or flattening (non-ulcerated lesion)                                  Yes                        100%                                            100%             Yes

  Day 90: \<100% re-epithelization (ulcer) or flattening (non-ulcerated lesion)                                 Yes                        100%                                            100%             Yes

  **Other efficacy parameters: stigma and cosmetic**                                                                                                                                                        

  Presence and grading of scar[\*\*](#t001fn002){ref-type="table-fn"}                                           NA                         100%                                            100%             Yes
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Depending on known side effect, safety profile, phase of development, drug class and route of administration

\*\* Will require standardization

As for eligibility criteria, it was agreed that parasitological confirmation by visualization of the parasite (amastigotes in smears, promastigotes in culture) or molecular biology testing (primary PCR) is required for a patient to be enrolled in clinical trials; *Leishmania* species identification is not required for enrolment but is required for data analysis. The need for baseline safety tests (hematology, liver and renal function) depends on the risks associated with the treatment (route of administration and the phase of development), the drug's chemical class, and the perceived or known liabilities of the treatment (expected toxicity).

As for the efficacy parameters, there was consensus about re-epithelization for ulcerated lesions and flattening for non-ulcerated lesions as primary efficacy measures. The majority of participants was for adding absence of induration as an efficacy parameter (though more difficult to standardize), while redness (inflammation) was thought to be not sufficiently reliable.

Even though the natural history and treatment response vary across the range of old and new world *Leishmania* species, it was agreed that initial cure should be assessed at Day 90--100 (Day 0 being the day of enrolment and Day 1 being the first day of treatment) since it provides the best chances to assess success or failure. In OWCL treatment trials, an additional earlier assessment at Day 42 should also be conducted and reported to capture the earlier clinical response observed in these species.

In addition, OWCL participants identified the need to document more clearly and quantify the rate of self-healing in *L*. *major*, in order to better inform decisions on follow-up and study design, such as the assessment of time-to-heal particularly after topical treatment, as a secondary outcome---which would require multiple assessments. NWCL participants discussed the need to collect evidence towards a future definition of "early failure" (before Day 42) based on the type of intervention/treatment being evaluated.

While it was acknowledged that, in some instances, treatment is provided until the lesion is considered cured (especially when evaluating topical or intralesional treatments), efforts should be made to report the number of cured subjects at day 42 and the initial cure at day 90.

Final cure should be assessed at Day 180 (6 months after initiating treatment); a 12-month follow-up was not deemed necessary. Nevertheless, NWCL participants identified the need to assess the ideal time of follow-up for final cure, and document the rate of late-responses and relapses between days 90--180 (3--6 months). This would provide important elements to understand the cost-effectiveness of a 6-month follow-up, and inform study design.

There was almost general agreement that time of follow-up is counted starting from the first day of treatment and not from the end of treatment. The main issue was how to deal with treatments of different duration. For instance, systemic antimonials are given for 14--30 days (see Tables [2](#pntd.0006141.t002){ref-type="table"} and [3](#pntd.0006141.t003){ref-type="table"}); an initial assessment at day 42 counting from treatment start means 12--15 to 28--31 days after the end of treatment, compared to e.g. thermotherapy, which may be given in one single treatment.

10.1371/journal.pntd.0006141.t002

###### Site characteristics in Old World settings.
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  Country                                         Afghanistan                                                                       Burkina-Faso                                                                                                  Ethiopia                                                                                      Ethiopia                                                                                  Iran                                                                                              Iran                                                                                                                                    Iran                                                                                                                               Morocco                                                           Tunisia                                                                            Turkey
  ----------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
  **Institution**                                 National Malaria and Leishmaniasis Control Programme                              Université Polytechnique de Bobo-Dioulasso                                                                    Armauer Hansen Research Institute (AHRI), Addis Ababa                                         University of Gondar, Gondar                                                              Shiraz University of Medical Sciences, Shiraz                                                     Tehran University of Medical Sciences                                                                                                   Emam Reza Hospital, Mashhad University of Medical Sciences                                                                         Department of parasitologic diseases, Ministry of Health, Rabat   Institut Pasteur, Tunis                                                            Akdeniz University, Antalya & Ege University, Bornova, Izmir
  **Area of work**                                Kabul and Balkh                                                                   Bobo-Dioulasso, Ouagadougou                                                                                   Addis Ababa, Silti, Ankober and Debretabor                                                    Gondar, Northen part of Ethiopia                                                          Shiraz and vicinity                                                                               Tehran                                                                                                                                  Mashhad                                                                                                                            Taza, Sefrou, Errachidia, Ouarzazate,Azilal and Chichaoua         Sidi-Bouzid, Kairoan and Gafsa mainly (*L*. *major*), Tataouine *(L*. *tropica)*   Antalya and Adana
  **Primary or referral center**                  primary                                                                           both                                                                                                          referral                                                                                      referral                                                                                  both                                                                                              both                                                                                                                                    both                                                                                                                               both                                                              both                                                                               primary
  **Clinical research (GCP) experience**          no                                                                                yes                                                                                                           yes                                                                                           yes                                                                                       yes                                                                                               yes                                                                                                                                     yes                                                                                                                                no                                                                yes                                                                                yes
  **National treatment guidelines**               yes                                                                               yes                                                                                                           incomplete                                                                                    yes                                                                                       yes                                                                                               yes                                                                                                                                     yes                                                                                                                                yes                                                               yes                                                                                yes
  **N. of cases in country**                      19589                                                                             532 in 2014 (investigator report)                                                                             342 (Investigators estimate 20,000--50,000)                                                   21148                                                                                     2555                                                                                              3368 (investigators estimate up to 10,000)                                                                                              3977                                                                                                                                                                                                                                                                                    
  **Number of cases seen per year**               17,000--20,000                                                                    2013: 128; 2014: 144                                                                                          \~1500                                                                                        \~ 100 per site                                                                           1200--1500                                                                                        250--500                                                                                                                                300--400                                                                                                                           100--400                                                          200--600                                                                           50 in Antalya; 300 in Adana
  **Leishmania species**                          *L*. *tropica*                                                                    *L*. *major*                                                                                                  *L*. *aethiopica*                                                                             *L*. *aethiopica*                                                                         *L*. *major*, *L*. *tropica*                                                                      *L*. *major*, *L*. *tropica*                                                                                                            *L*. *major*, *L*. *tropica*                                                                                                       *L*. *major*, *L*. *tropica*                                      *L*. *major*, *L*. *tropica*                                                       *L*. *major*, *L*. *tropica*, *L*. *infantum*
  **Type of diagnosis, species identification**   direct smear                                                                      direct smear, PCR, biopsy                                                                                     direct smear, PCR, culture                                                                    direct smear, PCR, culture species identification not done routinely                      direct smear, PCR, biopsy                                                                         direct smear, culture, PCR for all patients                                                                                             direct smear; selected cases: PCR and culture                                                                                      direct smear, PCR                                                 direct smear, PCR, culture                                                         direct smear
  **Age of subjects**                             \> 5 y.o.                                                                         adults                                                                                                        mainly 10--20 y.o.                                                                            teenagers and young adults                                                                adults and children                                                                               adults and children                                                                                                                     adults and children                                                                                                                adults and children                                               adults and children                                                                adults and children
  **Gender (F:M)**                                50:50                                                                             50:50                                                                                                         50:50                                                                                         50:50                                                                                     50:50                                                                                             35:65                                                                                                                                   50:50                                                                                                                              50:50                                                             50:50                                                                              50:50
  **Emerging or stable foci**                     stable                                                                            both)                                                                                                         both                                                                                          stable                                                                                    stable                                                                                            stable                                                                                                                                  stable                                                                                                                             both                                                              both                                                                               stable
  **Rural or (peri)urban setting**                both                                                                              both                                                                                                          both                                                                                          rural                                                                                     both                                                                                              both                                                                                                                                    urban                                                                                                                              both                                                              both                                                                               rural
  **Seasonality**                                 April-November                                                                    September-November                                                                                            almost year-round                                                                             year-round                                                                                Peak: September-March                                                                             Peak: September-March                                                                                                                   Peak: September-January                                                                                                            November-April                                                    September-March                                                                    September-March
  **Number of lesions**                           \>5                                                                               \>5                                                                                                           \~47% single                                                                                  1--2 in 80%                                                                               few to many                                                                                       mostly few, rarely multiple                                                                                                             mostly few, rarely multiple                                                                                                        few to many (1 to \> 6)                                           1--2                                                                               1--2
  **Type of lesion and size**                     papule, nodule, ulcer; different sizes                                            mostly papule and ulcer; 20--40 mm also papulonodular, nodule                                                 early lesions (\<6 months) up to 80% nodular; chronic lesions (\>6 months) \>60% ulcerative   patch, ulcer, induration, plaque; \~50 mm                                                 mostly ulcerated nodule or plaque; 15 mm                                                          mostly ulcer                                                                                                                            mostly papule and nodule; 20--40 mm                                                                                                nodule, ulcer, plaque; \< 40 mm                                   90% ulcer; 10--40 mm (mean 20 mm) also nodule and plaque                           mostly papule and nodule; 10--20 mm
  **Duration of lesion**                          months to years                                                                   2--6 months                                                                                                   months to years                                                                               months to years                                                                           months to years                                                                                   months to years                                                                                                                         weeks to years, usually 3--6 months in daily practice                                                                              *L*. *major*: 2--6 months; *L*. *tropica*: mean 12 months         *L*. *major*: 1--6 months; *L*. *tropica*: mean 12 months                          11 months
  **Other manifestations**                        lupoid, DCL                                                                                                                                                                                     MCL, DCL                                                                                      MCL, DCL                                                                                  erysepeloid, sporotrichoid, lupoid                                                                sporotrichoid                                                                                                                           lupoid, recidivans, erysipeloid, sporothricoid, zosteriform, DCL                                                                   sporotrichoid, lupoid, erysepeloid                                DCL                                                                                lupoid, chronic, erysepeloid, sporotrichoid
  **Treatment (type/dose)**                       IM antimonials 20mg/kg/d x 14-21d; IL injection based on size of lesion (2-4ml)   \<5 lesions: IL antimonials, 2--3 ml/d x 2 days \> 5 lesions: IM antimonials 20mg/kg/d x 21d, uo to 3 times   cryotherapy, IM antimonials 20mg/kg/d x 20d (max 850mg/day)                                   IM antimonials 20mg/kg/d x 30d, liposomal amphotericin B, paromomycin; oral miltefosine   cryotherapy one session per week, IM antimonials 20mg/kg/d x 15-20d; IL antimonials once a week   cryotherapy, heat therapy, IM antimonials 20 mg/kg/d x 14 days for *L*. *major*, 21 days for *L*. *tropica*; liposomal amphotericin B   cryotherapy, heat therapy, IM antimonials 20 mg/kg/d x 20-30d, IL antimonials x 1-2/week x 8--12 weeks, liposomal amphotericin B   IM antimonials 20mg/kg/21d IL antimonials 1-3ml x 2/week          IL antimonials, thermotherapy, cryotherapy                                         IM antimonials 20mg/kg/d x 20d, IL antimonials 1 ml/cm2 x 5--8 times, cryotherapy (monotherapy or combined with IL antimonials
  **Duration of follow up**                       1 month                                                                           until complete healing of lesions                                                                             3--6 months                                                                                   3--6 months                                                                               3--6 months in routine clinical setting, until complete healing of lesions                        until complete healing of lesions                                                                                                       3--6 months                                                                                                                        until complete healing of lesions                                 1--6 months                                                                        12 months after end of treatment (every 3 months)

10.1371/journal.pntd.0006141.t003

###### Site characteristics in New World settings.
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  Country                                             Bolivia                                                                  Brazil                                               Brazil                                                         Colombia                                                                                                Colombia                                                                                                                      Guatemala                                                       Panama                                                                  Peru                                                                    Venezuela
  --------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------
  **Institution**                                     Fundación Nacional de Dermatología, FUNDERMA. Santa Cruz de la Sierra    Serviço de Imunologia, Federal University of Bahia   Centro de Pesquisa René Rachou---FIOCRUZ, Belo Horizonte       Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali                          Programa de Estudio y Control de Enfermedades Tropicales (PECET), Medellín                                                    Center for Health Studies, Universidad del Valle de Guatemala   Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá          Hospital Cayetano Heredia, Universidad Peruana Cayetano Heredia, Lima   Instituto de Biomedicina Dr Jacinto Convit. Caracas Venezuela
  **Area of work**                                    Santa Cruz and referred patients                                         Corte de Pedra, Tancredo Neves, Bahia                Minas Gerais                                                   Mainly South-western                                                                                    Caribbean coast, Amazon, Andean valleys, Pacific coast and eastern plains                                                     El Peten and Alta Verapaz                                       Panama City and refereed patients                                       Andean and jungle areas                                                 Metropolitan area
  **Primary or referral center**                      referral                                                                 both                                                 referral                                                       both                                                                                                    referral                                                                                                                      referral                                                        referral                                                                referral                                                                referral
  **Clinical research (GCP) experience**              yes                                                                      yes                                                  yes                                                            yes                                                                                                     yes                                                                                                                           yes                                                             yes                                                                     yes                                                                     yes
  **National treatment guidelines**                   yes                                                                      yes                                                  yes                                                            yes                                                                                                     yes                                                                                                                           yes                                                             yes                                                                     yes                                                                     yes
  **N. of cases in country/ (WHO official figures**   1683                                                                     19402                                                11433                                                          254                                                                                                     1581                                                                                                                          5888 (investigators estimate up to 8000)                        1661                                                                                                                                            
  **Number of cases seen per year**                   150--200                                                                 800--1,500                                           \~90                                                           \~200                                                                                                   200                                                                                                                           \~100                                                           \~100                                                                   350--400                                                                150
  **Leishmania species**                              *L*. *braziliensis*, *L*. *guyanensis*, *L*. *mexicana*                  *L*.*braziliensis*                                   *L*.*braziliensis (95%)*                                       *L*. *panamensis*, *L*. *braziliensis*, *L*. *guyanensis*                                               *L*.*panamensis*, *L*.*braziliensis*                                                                                          *L*. *braziliensis*, *L*. *mexicana*                            *L*. *panamensis*, *L*. *guyanensis*, *L*. *braziliensis*               *L*. *braziliensis*, *L*. *peruviana*, *L*. *guyanensis*                *L*. *braziliensis and L*. *mexicana*
  **Type of diagnosis, species identification**       direct smear; capability for culture and PCR                             PCR                                                  direct smear                                                   direct smear, PCR, biopsy, monoclonal antibodies and isoenzymes                                         direct smear, PCR                                                                                                             direct smear, PCR                                               direct smear, culture, PCR, DTA                                         direct smear, PCR, culture; species identification                      direct smear, culture, PCR, biopsy
  **Age of subjects**                                 young adults                                                             mainly adults                                        young adults                                                   adults and children                                                                                     adults and children                                                                                                           adults and children                                             adults and children                                                     adults and children                                                     adults
  **Gender (F:M)**                                    10:90                                                                    30:70                                                30:70                                                          20:80                                                                                                   50:50 (civilian population) 1:99 (military population)                                                                        45:55                                                           33:67                                                                   50:50                                                                   38:62
  **Emerging or stable foci**                         stable                                                                   stable                                               stable                                                         stable                                                                                                  stable                                                                                                                        stable                                                          stable                                                                  stable                                                                  stable
  **Rural or (peri)urban setting**                    both                                                                     rural                                                peri-urban                                                     rural                                                                                                   both                                                                                                                          rural                                                           both                                                                    rural                                                                   both
  **Seasonality**                                     all year-round                                                           all year                                             all year-round                                                 year-round                                                                                              All year-round                                                                                                                all year-round                                                  peak: March to July                                                     peak: January-June                                                      all year-round
  **Number of lesions**                               1--2                                                                     single                                               70% single                                                     1 (1--3)                                                                                                2                                                                                                                             1--2                                                            2--3                                                                    80% single                                                              1--2
  **Type of lesion and size**                         ulcer; 25--30 mm                                                         90% ulcer; 15 mm                                     70% ulcer; 80%\<40 mm                                          80% ulcer; 90% \<50 mm diameter                                                                         mainly ulcer (\~80%); 20 mm                                                                                                   90% ulcers; 10--20 mm                                           90% ulcer; 10--20 mm                                                    80% ulcer; 70% \<30 mm                                                  80% ulcer; 70% \<30 mm
  **Duration of lesion**                              3--5 months in 90% cases                                                 mean 1.5 month                                       \~3 months                                                     \~2 months                                                                                              2 months                                                                                                                      3--4 months                                                     3--4 weeks                                                              mostly \<3 months                                                       1 month
  **Other manifestations**                            lymphangitis (35%), MCL (3--15%), DCL (5%)                               MCL (3%), DCL(4%), atypical (3%)                     lymphangitis (10--15%)                                         lymphangitis (18%), mucosal involvement (4%), disseminated (sporadic)                                   lymphangitis, MCL                                                                                                             lymphangitis (5%)                                               lymphangitis (10--20%)                                                  lymphangitis (20--30%)---depending on time of disease                   lymphangitis (\<10%)
  **Treatment (type/dose)**                           IM antimonials 20 mg/kg/d x 20 d (85%); amphotericin B 0.5--1 mg (15%)   IM antimonials 20 mg/kg/d x 20 d                     IL antimonials (60%); IM antimonials 20 mg/kg/d x 20 d (40%)   IM antimonials 20 mg/kg/d x 20 d. oral miltefosine (1.5--2.5 mg/kg/day); thermotherapy IL antimonials   IM antimonials: 20 mg/kg/day x 20d oral miltefosine 2.5 mg/kg/day x 28d pentamidine: 3--4 mg/kg/d x 3 doses every other day   IM antimonials 20 mg/kg/d x 20 d                                IM antimonials 20 mg/kg/d x 20 d; amphotericin B for rescue treatment   IM antimonials 20 mg/kg/d x 20 d, amphotericin B rescue treatment       IM antimonials, no exact dose recommended; oral miltefosine
  **Duration of follow up**                           6 months                                                                 6 months                                             12 months                                                      6 months                                                                                                6 months                                                                                                                      3--6 months                                                     3--6 months                                                             12 months                                                               5 years

It was also agreed that treatment failure should be defined at Day 42 as less than 50% re-epithelialization (if an ulcer) or flattening (if a non-ulcerated lesion); and at Day 90 as less than 100% re-epithelialization or flattening, respectively.

It was suggested that the presence and grading of scars (cosmetic effects) should be assessed in a standardized way and included in future long-term treatment evaluation, as this represents an important parameter for patients because of the related stigma and social consequences. The results of qualitative studies using in-depth semi-structured CL patient interviews aimed at understanding the CL patient's needs and expectations from treatment (paper in preparation) will also help inform study design.

CL trial site characteristics and capacities {#sec009}
--------------------------------------------

Site characteristics for OWCL and NWCL are summarized in Tables [2](#pntd.0006141.t002){ref-type="table"} and [3](#pntd.0006141.t003){ref-type="table"} respectively.

### About the sites {#sec010}

'Site' here refers to a single or multiple treatment sites with different catchment areas covered by one group. Of the OWCL sites, 3 are referral centers, 2 primary and 5 both; for NWCL, 7 are referral and two both primary and referral. Capacity for good clinical practice (GCP) trials exists in 8/10 OWCL sites and 9/9 NWCL sites.

### About the disease: OWCL {#sec011}

Species and diagnosis: Cases of both *L*. *major* and *L*. *tropica* cases are seen at 6/10 sites (one also *L*. *infantum*), while 2 sites have one species each and 2 have *L*. *aethiopica*. Parasitological diagnosis by direct smear is done at all sites. Capacity for polymerase--chain reaction (PCR) exists at 8 sites and culture at 5, though techniques are not always used routinely.

Age and Sex: All ages are affected in 7/10 sites. *L*. *aethiopica* affects mostly older children, adolescents and young adults. OWCL affects equally women and men, with more men being seen only in Iran.

Endemicity: Six out of 10 sites have stable transmission, while 4 see patients from both emerging and stable foci. There is no obvious pattern relating age and transmission. Burkina-Faso has a stable focus in Ougadougou and a newer one in Bobo-Dioulasso.

Setting: Patients seen at 6/10 sites are from both rural and periurban settings. In Burkina-Faso the Ougadougou focus is periurban, while the one in Bobo-Dioulasso is rural.

Seasonality: Cases are seen mostly in fall and winter at 7/10 sites with variable durations. Year-round transmission occurs in Ethiopia.

Number of lesions: Patients tend to present with few (1--2) lesions at 4 sites. Several lesions (\>5) are seen in Afghanistan (*L*. *tropica*) and Burkina-Faso (*L*. *major*). The number of lesions varies in Iran and Morocco. There is no obvious pattern relating species and number of lesions.

Morphology and duration of lesions: Ulcerated, papular and nodular forms are seen across all sites. Lesions are up to 40 mm at 4 sites and up to 20 mm in 2 other sites. Other manifestations include disseminated (DCL, 5 sites), and others like lupoid, erysepeloid, sporotrichoid. *L*. *aethiopica* manifestations include DCL and mucocutaneous (MCL) forms.

Patients present with lesions that have lasted variably from weeks to years across the various sites. Tunisia and Morocco report that *L*. *major* patients seek treatment when lesions have been present for up to 6 months, *L*. *tropica*'s 12 months.

### About the disease: NWCL {#sec012}

Species and Diagnosis: *L*. *braziliensis* is the most frequent species in 6/9 sites and present also in the other 3, where *L*. *panamensis* predominates. Other species found are *L*. *mexicana* and *L*. *guyanensis*. Parasitological diagnosis by direct smear is the technique used at all but one site in Brazil. Polymerase--chain reaction (PCR) exists at 8 sites and culture at 4 but these are not always done routinely.

Age and Sex: All ages are affected in 5/9 sites. Men represent approximately two-thirds of patients at 5 sites and 90% at another one, while the other 3 sites have almost equal representation of women and men.

Endemicity: All sites have stable transmission

Setting: Patients seen at 4/9 sites are from both rural and periurban settings, 4 rural and one periurban.

Seasonality: Cases are seen all year-round in all sites, some with seasonal peaks.

Number of lesions: Patients tend to present with single or few (up to 3) lesions.

Morphology and duration of lesions: Ulcerated lesions predominate at all sites. Other manifestations include lymphangitis (5--35% at 8/9 sites), MCL (3 sites) and DCL (2 sites).

Patients present with lesions that have lasted from 3 weeks to 5 months, but mostly not exceeding 3 months (7 sites). Bolivia reports seeing increasing numbers of chronic cases with disease lasting for over 18 months.

### About treatment and follow-up: OWCL {#sec013}

Treatment: Intramuscular (IM) antimonials at 20 mg/kg/day for 14--30 days is used at 8/9 sites. Intralesional (IL) antimonials are also used at 7 sites at variable dosages (volume injected, number of doses, and duration of treatment). Choice of treatment may depend on the number of lesions (IL if less than 5 lesions, otherwise IM in Burkina-Faso) or species (IM antimonials are given daily for 14 days in case of *L*. *major* and 21 if *L*. *tropica* at one site in Iran). In addition, local antiseptics are regularly applied at 2 sites. Cryotherapy and/or thermotherapy are also used at 5 sites (alone or combined with IL injections). Other medications available are liposomal amphotericin B (2 sites in Iran), paromomycin and oral miltefosine at one site in Ethiopia.

Duration of follow-up: Practice varies greatly; 3 sites follow patients up routinely until complete healing of lesions; others follow patients up for a fixed duration from 1 month to 12 months (3--6 months in 4 sites).

### About treatment and follow-up: NWCL {#sec014}

Treatment: Intramuscular (IM) antimonial at 20 mg/kg/day for 20 days is used at all sites. Second-line treatment consists of amphotericin B deoxycholate at 3 sites, oral miltefosine (2 sites), or pentamidine (1 site). Intra-lesional antimonials are used only in one site in Colombia and one in Brazil.

Duration of follow-up: Six (6) sites follow patients up for 6 months, 2 for 12 months, and one for 5 years.

Discussion {#sec015}
==========

The consensus reached among participants during the two meetings allows standardization of future clinical research across OWCL and NWCL sites---a major issue which has hampered our collective ability to generate strong evidence for treatment guidelines and policy. We encourage CL researchers to adopt and adapt if so required the proposed parameters and outcomes in their future trials. Furthermore, the expertise afforded between the two sets of clinical sites provides the basis for a powerful consortium with potential for extensive, standardized assessment of interventions for CL.

[^1]: The opinions expressed in this paper are those of the authors and may not reflect those of their employing organizations. PO, LG and JARP are staff of the World Health Organization (WHO). The authors alone are responsible for the views expressed in this publication and it does not necessarily represent the decisions, policy, or views of the WHO. Remaining authors have declared that no competing interests exist.
